Spectrum Pharmaceutecals Inc (SPPI)

[Ville7]

expected newsflow ( (c) Ville ):

2017-09-09 11:00 - 12:30: poziotinib Hanmi Her2 BC trial "proffered paper" presentation at http://www.esmo.org/Conferences/ESMO-2017-Congress in Madrid

2017-10-15 - 2017-10-18: pozitinib EGFR/HER exon20 single agent "initial clinical data" from MD Anderson trial at http://wclc2017.iaslc.org/ in Yokohama

Q3 2017: Start ROLONTIS RECOVER trial (218 patients)

Q3 2017: Start QAPZOLA trial 8mg 2:1 (425 patients)

Q3 2017: Start SPPI sponsored multicenter trial pozitinib EGFR/HER exon20 single agent

Q1 2018: Enrollment completion for ROLONTIS RECOVER trial

Q1 2018: Topline Data for ROLONTIS ADVANCE trial (405 patients)

Q1 2018: Try to get "breakthrough designation" for pozitinib in EGFR/HER exon20 NSCLC on basis of MD Anderson trial

Q2 2018: Data for ROLONTIS ADVANCE trial at ASCO

Q3 2018: Topline Data for ROLONTIS RECOVER trial

Q4 2018: File BLA for ROLONTIS on basis of ADVANCE and RECOVER